CAMBRIDGE, United Kingdom, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, a pharmaceutical company based in Cambridge, UK, dedicated to the discovery and development of novel small ...

Astex Pharmaceuticals, Inc. has announced that clinical development of its lung cancer drug, amuvatinib (MP-470), has been discontinued. Amuvatinib is a multi-targeted tyronsine kinase inhibitor ...

Ibrance and Kisquali both raise the risk of neutropenia, but Kisquali also comes with heart rhythm risk and liver toxicity, while severe diarrhoea has been seen in patients taking Verzenio.

ASTX528 is a novel small molecule CBP/p300 HAT domain inhibitor with potent in vivo activity and a favourable safety profile in preclinical species that was discovered by Astex using its proprietary ...

Astex Pharmaceuticals is set to make five key data presentations at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics in Barcelona, Spain. The Astex presentations at the ...

A brilliant idea for helping cancer patients is just that – an idea – until it is put into practice. But turning research into something that can improve patient outcomes and benefit healthcare ...